Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2020 | AL amyloidosis: Hot topics from ISA 2020

Vaishali Sanchorawala • 15 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Big topics for discussion at this year’s ISA meeting include measurable residual disease (MRD) assessment and hematological response measurement in AL amyloidosis. Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses these hot topics from ISA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Vaishali Sanchorawala

Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2025
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
5:43
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
Vaishali Sanchorawala • 8 Dec 2025
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
1:03
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
Vaishali Sanchorawala • 8 Dec 2025
Amyloidosis Sessions: Highlights from ASH 2024
Amyloidosis Sessions: Highlights from ASH 2024
Ashutosh Wechalekar et al. • 8 Dec 2024

Related Videos

Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
3:29
Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
Aditya Nair • 25 Sep 2026
BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals